Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-05

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Microvascular dysfunction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM) and can be visualized non-invasively using cardiac magnetic resonance (CMR) perfusion imaging. In parallel, the six-minute walk test (6MWT) is an established clinical tool to assess submaximal exercise capacity in patients with structural heart disease. Despite its widespread use, the relationship between objective changes in myocardial perfusion and functional improvements assessed by the 6MWT remains insufficiently explored in patients with HOCM on optimal medical therapy (OMT).

Aim:This study aims to evaluate whether changes in functional capacity, measured by the 6MWT, correlate with changes in myocardial perfusion reserve (MPR) in HOCM patients treated with OMT.

Methods: We will include patients diagnosed with obstructive HCM who previously underwent clinically indicated CMR perfusion scans for risk stratification. These patients are regularly followed in the HCM outpatient clinic of the Medical University of Vienna, where standardized 6MWTs are performed in routine care. Approximately one year after the baseline CMR, a follow-up CMR will be conducted to assess changes in perfusion parameters. This second CMR is clinically justified for improved individual risk stratification as recommended by the 2023 ESC Guidelines on Cardiomyopathies.

The primary objective is to assess the correlation between the change in the walking distance in the 6MWT and the change in MPR over a one-year interval. Secondary endpoints include changes in myocardial blood flow (MBF) at rest and during pharmacological stress. All assessments will be integrated with clinical, echocardiographic, and laboratory evaluations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients - TRICHAMPION STUDY

NCT01614717

Hypertrophic Cardiomyopathy With Obstruction

COMPLETED NA

Septal Ablation for Obstructive HCM

NCT06277960

Hypertrophic Obstructive Cardiomyopathy (HOCM)

ACTIVE_NOT_RECRUITING NA

Biventricular Pacing in Hypertrophic Cardiomyopathy After Aortic Valve Replacement

NCT01081093

Hypertrophic Cardiomyopathy

COMPLETED NA

Speckle Tracking Echocardiography Analysis of Left Ventricular Myocardium After Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy

NCT04777188

Hypertrophic Obstructive Cardiomyopathy

COMPLETED NA

Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy

NCT03450252

Cardiomyopathy, Hypertrophic

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Obstructive Cardiomyopathy \(HOCM\)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mavacamten in clinical routine use

Clinical observation of mavacamten use

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* Willingness to provide written informed consent
* Diagnosis of obstructive HCM based on ESC 2023 criteria
* Planned CMR with myccardial perfusion for clinical purposes
* Receiving guideline-conform OMT
* Ability and willingness to undergo follow-up imaging and testing
* Written informed consent

Exclusion Criteria

* Claustrophobia or other contraindication for CMR imaging
* Significant coronary artery disease and/or prior stent implantation or coronary artery bypass graft surgery
* History of sudden cardiac arrest or sustained ventricular arrhythmia 12 months prior to screening
* Glomerular filtration rate \< 30ml/min/m2
* Significant hepatic impairment defined as 3x upper limit of normal of transaminases, total bilirubin, or alkaline phosphatase; hepatic cirrhosis
* Known allergy to contrast agent
* Alternative disease causing hypertrophic cardiomyopathy (e.g. cardiac amyloidosis, Morbus Fabry)
* Pregnant women (and women with childbearing potential with desire for pregnancy)
* Breastfeeding women
* Unwillingness to comply with the study protocol and its procedures

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No